Pharmacointeraction Network Models Predict Unknown Drug-Drug Interactions

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Cami, Aurel ^a,b   Manzi, Shannon ^a   Arnold, Alana ^a   Reis, Ben Y ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE DRUG REACTION; ARTICLE; CONTROLLED STUDY; DRUG DATABASE; DRUG INTERACTION; DRUG SAFETY; NONBIOLOGICAL MODEL; PREDICTIVE PHARMACOINTERACTION NETWORK MODEL; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY;

DRUG INTERACTIONS; HUMANS; MODELS, THEORETICAL; PHARMACEUTICAL PREPARATIONS; ROC CURVE;

EID: 84876431695     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061468     Document Type: Article

References (37)

1. Gottlieb S, (1999) Antihistamine drug withdrawn by manufacturer. British Medical Journal 319: 7.
2. Trenk D, (2005) Market withdrawal of cisapride. European Journal of Clinical Pharmacology 61: 698-698.
3. SoRelle R, (1998) Withdrawal of Posicor from market. Circulation 98: 831-832.
4. Robertson S, Penzak S, Arthur JA, Darrell RA, Charles ED, et al. (2007) Drug Interactions. Principles of Clinical Pharmacology (Second Edition). Burlington: Academic Press. 229-247.
5. Lin JH, (2000) Sense and nonsense in the prediction of drug-drug interactions. Current Drug Metabolism 1: 305-331.
6. Patsalos PN, Perucca E, (2003) Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. The Lancet Neurology 2: 347-356.
7. Opie LH, (2000) Adverse cardiovascular drug interactions. Current Problems in Cardiology 25: 628-632.
8. Ekins S, Wrighton SA, (2001) Application of in silico approaches to predicting drug-drug interactions. Journal of Pharmacological and Toxicological Methods 45: 65-69.
9. Butina D, Segall MD, Frankcombe K, (2002) Predicting ADME properties in silico: methods and models. Drug Discovery Today 7: S83-S88.
10. Ekins S, (2003) In silico approaches to predicting drug metabolism, toxicology and beyond. Biochemical Society Transactions 31: 611-614.
11. Hudelson MG, Ketkar NS, Holder LB, Carlson TJ, Peng CC, et al. (2008) High confidence predictions of drug-drug interactions: Predicting affinities for cytochrome P450 2C9 with multiple computational methods. Journal of Medicinal Chemistry 51: 648-654.
12. Shou MG, (2005) Prediction of pharmacokinetics and drug-drug interactions from in vitro metabolism data. Current Opinion in Drug Discovery & Development 8: 66-77.
13. Obach RS, (2009) Predicting drug-drug interactions from in vitro drug metabolism data: challenges and recent advances. Current Opinion in Drug Discovery & Development 12: 81-89.
14. Foti RS, Wahlstrom JL, (2008) Prediction of CYP-mediated drug interactions in vivo using in vitro data. Idrugs 11: 900-905.
15. Lu C, Hatsis P, Berg C, Lee FW, Balani SK, (2008) Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. II. In vitro-in vivo correlation with ketoconazole. Drug Metabolism and Disposition 36: 1255-1260.
16. Lounkine E, Keiser MJ, Whitebread S, Mikhailov D, Hamon J, et al. (2012) Large-scale prediction and testing of drug activity on side-effect targets. Nature 486: 361-367.
17. Whitebread S, Hamon J, Bojanic D, Urban L, (2005) In vitro safety pharmacology profiling: an essential tool for successful drug development. Drug Discovery Today 10: 1421-1433.
18. Hisaka A, Ohno Y, Yamamoto T, Suzuki H, (2010) Prediction of pharmacokinetic drug-drug interaction caused by changes in cytochrome P450 activity using in vivo information. Pharmacology & Therapeutics 125: 230-248.
19. van Puijenbroek EP, Egberts ACG, Heerdink ER, Leufkens HGM, (2000) Detecting drug-drug interactions using a database for spontaneous adverse drug reactions: an example with diuretics and non-steroidal anti-inflammatory drugs. European Journal of Clinical Pharmacology 56: 733-738.
20. Almenoff JS, DuMouchel W, Kindman LA, Yang XH, Fram D, (2003) Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post-marketing setting. Pharmacoepidemiology and Drug Safety 12: 517-521.
21. Noren GN, Sundberg R, Bate A, Edwards IR, (2008) A statistical methodology for drug-drug interaction surveillance. Statistics in Medicine 27: 3057-3070.
22. Tatonetti NP, Denny JC, Murphy SN, Fernald GH, Krishnan G, et al. (2011) Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels. Clin Pharmacol Ther 90: 133-142.
23. Liben-Nowell D, Kleinberg J, (2007) The link-prediction problem for social networks. Journal of the American Society for Information Science and Technology 58: 1019-1031.
24. Clauset A, Moore C, Newman MEJ, (2008) Hierarchical structure and the prediction of missing links in networks. Nature 453: 98-101.
25. Hopkins AL, (2008) Network pharmacology: the next paradigm in drug discovery. Nature Chemical Biology 4: 682-690.
26. Barabasi AL, Gulbahce N, Loscalzo J, (2011) Network medicine: a network-based approach to human disease. Nature Reviews Genetics 12: 56-68.
27. Vidal M, Cusick ME, Barabasi AL, (2011) Interactome Networks and Human Disease. Cell 144: 986-998.
28. Chang RL, Xie L, Xie L, Bourne PE, Palsson BO (2010) Drug Off-Target Effects Predicted Using Structural Analysis in the Context of a Metabolic Network Model. Plos Computational Biology 6.
29. Takarabe M, Okuda S, Itoh M, Tokimatsu T, Goto S, et al. (2008) Network analysis of adverse drug interactions. Genome Inform 20: 252-259.
30. Hu TM, Hayton WL, (2010) Architecture of the drug-drug interaction network. Journal of Clinical Pharmacy and Therapeutics 36: 135-143.
31. Cami A, Arnold A, Manzi S, Reis B, (2011) Predicting adverse drug events using pharmacological network models. Science Translational Medicine 3: 114ra127.
32. Huang R, Southall N, Wang Y, Yasgar A, Shinn P, et al. (2011) The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical Genomics. Science Translational Medicine 3.
33. Cami A, Deo N, (2008) Techniques for analyzing dynamic random graph models of web-like networks: An overview. Networks 51: 211-255.
34. Tatonetti NP, Fernald GH, Altman RB, (2011) A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports. JAMIA 19: 79-85.
35. Wang LM, Wong M, Lightwood JM, Cheng CM, (2010) Black Box Warning Contraindicated Comedications: Concordance Among Three Major Drug Interaction Screening Programs. Annals of Pharmacotherapy 44: 28-34.
36. Saverno KR, Hines LE, Warholak TL, Grizzle AJ, Babits L, et al. (2011) Ability of pharmacy clinical decision-support software to alert users about clinically important drug-drug interactions. Journal of the American Medical Informatics Association 18: 32-37.
37. Abarca J, Malone DC, Armstrong EP, Grizzle AJ, Hansten PD, et al. (2004) Concordance of severity ratings provided in four drug interaction compendia. Journal of the American Pharmacists Association 44: 136-141.